Revolution Medicines, Inc. (RVMD)

NASDAQ: RVMD · Real-Time Price · USD

205.57

-2.31 (-1.11%)

At close: Aug 31, 2026, 4:00 PM EDT

205.80

+0.23 (0.11%)

After-hours: Aug 31, 2026, 7:58 PM EDT

Revolution Medicines Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	815.44	383.75	543.06	696.15	161.41	108.5
Short-Term Investments	3,123	1,642	1,746	1,157	483.53	468.56
Cash & Short-Term Investments	3,938	2,026	2,289	1,853	644.94	577.05
Cash Growth	84.26%	-11.52%	23.55%	187.31%	11.77%	30.93%
Receivables	-	-	-	1.25	4.67	5.93
Prepaid Expenses	90.37	49.36	38.33	25.07	10.57	6.79
Total Current Assets	4,028	2,075	2,328	1,879	660.19	589.77
Property, Plant & Equipment	162.45	165.28	141.82	100.01	73.74	71.24
Goodwill	14.61	14.61	14.61	14.61	14.61	14.61
Other Intangible Assets	55.8	55.8	56.67	57.74	58.81	59.88
Long-Term Deferred Charges	-	-	-	-	-	0.5
Other Long-Term Assets	62.07	43.79	17.57	10.06	4.59	2
Total Assets	4,323	2,355	2,558	2,062	811.93	737.99

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	88.42	64.62	54.43	61.79	21.31	14.06
Accrued Expenses	243.74	201.48	96.03	70.8	28.94	27.41
Current Portion of Leases	16.75	16.47	12.87	7.37	6.77	6.21
Current Unearned Revenue	-	-	-	-	4.46	12.36
Other Current Liabilities	5.15	7.86	0.58	3.9	0.51	0.31
Total Current Liabilities	354.06	290.42	163.91	143.85	61.98	60.35
Long-Term Debt	1,036	268.45	-	-	-	-
Long-Term Leases	137.74	142.23	122.97	80.58	57.43	60.42
Long-Term Unearned Revenue	-	-	-	-	-	6.57
Long-Term Deferred Tax Liabilities	2.35	2.35	2.35	3.12	7.03	7.44
Other Long-Term Liabilities	186.9	19.75	3.86	7.97	0.3	0.63
Total Liabilities	1,717	723.21	293.1	235.51	126.74	135.42

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.02	0.02	0.02	0.02	0.01	0.01
Additional Paid-In Capital	6,579	4,497	4,002	2,963	1,388	1,056
Retained Earnings	-3,967	-2,869	-1,738	-1,138	-701.34	-452.64
Comprehensive Income & Other	-5.95	3.24	1.32	0.54	-1.78	-0.38
Total Common Equity	2,606	1,631	2,265	1,826	685.19	602.57
Shareholders' Equity	2,606	1,631	2,265	1,826	685.19	602.57
Total Liabilities & Equity	4,323	2,355	2,558	2,062	811.93	737.99

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	1,190	427.15	135.84	87.94	64.21	66.63
Net Cash (Debt)	2,747	1,599	2,153	1,765	580.74	510.42
Net Cash Growth	56.17%	-25.77%	22.01%	203.93%	13.78%	25.08%
Net Cash Per Share	13.86	8.41	12.84	15.60	7.20	7.01
Filing Date Shares Outstanding	214.34	198.17	185.91	164.69	90.49	74.19
Total Common Shares Outstanding	214.24	197	185.9	164.67	90.41	74.14
Working Capital	3,674	1,785	2,164	1,735	598.2	529.42
Book Value Per Share	12.16	8.28	12.19	11.09	7.58	8.13
Tangible Book Value	2,536	1,561	2,194	1,754	611.77	528.08
Tangible Book Value Per Share	11.84	7.92	11.80	10.65	6.77	7.12
Machinery	44.73	39.38	31.44	28.09	21.74	14.98
Construction In Progress	0.11	0.05	0.39	0.51	-	0.13
Leasehold Improvements	22.6	22.28	14.28	11.95	11.4	7.25

SEC Filings: 10-K · 10-Q